Synthesis of cationic β-cyclodextrin functionalized silver nanoparticles and their drug-loading applications

Area of Science:

• Materials Science
• Nanotechnology
• Biomedical Engineering

Background:

• Silver nanoparticles (AgNPs) possess unique properties driving research in synthesis and biomedical uses.
• Cationic β-cyclodextrin (C-β-CD) offers potential for nanoparticle modification and drug delivery due to its structure.

Purpose of the Study:

• To synthesize C-β-CD modified silver nanoparticles (CβCD-AgNPs) using C-β-CD as a reducing and stabilizing agent.
• To explore the drug-loading capacity of CβCD-AgNPs using thymol as a model drug, leveraging C-β-CD's inclusion complexation.
• To characterize the synthesized nanoparticles and evaluate their drug-loading performance.

Main Methods:

• Synthesis of CβCD-AgNPs using C-β-CD as reducing and stabilizing agent.
• Characterization via UV-vis, XRD, SEM, TEM, zeta potential, 1H-NMR, and FT-IR.
• Drug loading evaluation using UV-vis and HS-SPME-GC-MS, with TEM for size analysis post-loading.

Main Results:

• CβCD-AgNPs were successfully synthesized, confirmed by UV-vis and XRD.
• SEM and TEM revealed well-dispersed nanoparticles (3-13 nm) stabilized by C-β-CD, preventing aggregation.
• NMR and FT-IR confirmed C-β-CD encapsulation and reduction of AgNPs.
• Drug loading of thymol onto CβCD-AgNPs was demonstrated, evidenced by nanoparticle size increase.

Conclusions:

• C-β-CD is effective in synthesizing and stabilizing silver nanoparticles.
• The developed CβCD-AgNPs exhibit promising drug-loading capabilities via inclusion complexation.
• This approach offers a novel platform for developing functionalized nanoparticles for biomedical applications.